Oncology Brothers: Practice-Changing Cancer Discussions

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of Zanidatamab, a bispecific HER2 antibody, for HER2 amplified, unresectable, locally advanced, or metastatic biliary tract cancer. Join us as we discuss the HERIZON-BTC-01 study with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center and one of the study's authors. We explore the significance of HER2 testing in biliary tract cancers, the study's design, key findings, and the implications for treatment strategies in the community oncology setting. Key topics include: • Overview of biliary tract cancer and its treatment landscape • Study design and patient characteristics from the HERIZON-BTC-01 trial • Key findings, including overall response rates and duration of response • The importance of HER2 testing and its implications for treatment sequencing • Side effect profiles and management strategies for Zanidatamab • Future directions and ongoing clinical trials Don't miss this insightful discussion that highlights the exciting advancements in HER2-targeted therapies for biliary tract cancer. Make sure to subscribe for more updates on recent FDA approvals, treatment algorithms, and conference highlights. We look forward to seeing you at GI ASCO 2025 in person! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Welcome to the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. John Allan from New York Presbyterian Hospital to discuss the latest highlights from ASH 2024, focusing on Chronic Lymphocytic Leukemia (CLL). We dived into three key studies: 1.⁠ ⁠SEQUOIA Update: Discover how this study led to the approval of Zanubrutinib in the frontline setting and its impressive progression-free survival rates compared to traditional chemotherapy. 2.⁠ ⁠AMPLIFY Study: Learn about the exciting combination of Acalabrutinib with Venetoclax and Obinutuzumab, and how it may pave the way for the first oral doublet/triplet combination approval in the U.S. 3.⁠ ⁠Ongoing Trials: We touch on the CELESTIAL TN-CLL trial and the promising combination of Zanubrutinib with Sonrotoclax, a new BCL-2 inhibitor. Additionally, we discuss the evolving role of CAR-T therapy in CLL, especially for patients who have progressed through multiple lines of treatment. Join us for an insightful discussion on the future of CLL treatment options, the importance of balancing efficacy and side effects, and the exciting developments in the field. Don't forget to check out our other ASH and SABCS 2024 discussions! Subscribe to stay updated on the latest in oncology research and treatments! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Dr. Jason Westin, a lymphoma expert at MD Anderson, and Dr. Surbhi Sidana, who leads Stanford's Myeloma CAR-T program, dive into the intricacies of CAR-T cell therapy. They discuss its powerful mechanism and its application in treating cancers. The conversation highlights acute side effects like cytokine release syndrome and neurotoxicity, alongside strategies for their management. Chronic side effects, including infection risks and monitoring practices, are also explored, providing vital insights for oncologists on patient care.

Dr. Uma Borate, a leukemia treatment expert from The Ohio State University, joins the hosts for an insightful discussion on breakthroughs from ASH 2024. They delve into the promising KOMET 007 study on the Menin inhibitor Ziftomenib, noting its effectiveness for patients with specific genetic mutations. The conversation shifts to the comparison between CPX351 and traditional 7+3 induction therapies, revealing key insights about response rates. Additionally, they explore the role of Venetoclax in treating patients without actionable mutations, emphasizing NGS testing's vital role in targeted therapies.

In the second episode of a 4-part podcast series on HCC, the Oncology Brothers, Drs Rahul and Rohit Gosain, host a podcast discussion between Dr Lorenza Rimassa and Prof. Arndt Vogel on 2nd line treatment selection in advanced HCC and when to switch. The discussion covers a range of topics, including 2nd line options for advanced HCC after progression on 1st line TKIs and IO-based therapies, as well as: How to approach sequencing in clinical practice The available data supporting sequencing strategies When to switch to 2nd line therapy and what to consider when doing so This is the second video podcast episode in a 4-part series. Access the rest of the series here: Part 1 - The use of IO in unresectable HCC Part 3 - Intermediate HCC: treatment options and strategies (coming soon) Part 4 - The evolving role of IO in intermediate HCC (coming soon)   Clinical takeaways Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life. Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation.   Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!   Website: http://www.oncbrothers.com/   X/Twitter: https://twitter.com/oncbrothers   Contact us at info@oncbrothers.com

Welcome to another episode of the Oncology Brothers! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the complexities of managing side effects associated with antibody drug conjugates (ADCs). Joined by expert guests Dr. Tian Zhang, a GU medical oncologist from UT Southwestern, and Dr. Erika Hamilton from Sarah Cannon Research Institute, the discussion focuses on three key ADCs: Enfortumab vedotin, Sacituzumab govitecan, and Trastuzumab deruxtecan (TDXD). Episode Highlights: •⁠  ⁠Enfortumab vedotin: Learn about the common side effects such as skin toxicities, hyperglycemia, and neuropathy, and how to manage them effectively in clinical practice. •⁠  ⁠Sacituzumab govitecan: Explore the challenges of neutropenia, diarrhea, and fatigue, and the importance of individualized patient care. •⁠  ⁠Trastuzumab deruxtecan (TDXD): Understand the critical side effects including nausea, fatigue, and interstitial lung disease (ILD), and the strategies for prevention and management. This episode emphasizes the importance of recognizing and acting on side effects that can significantly impact patient outcomes. Whether you're a healthcare professional or someone interested in oncology, this discussion will provide valuable insights into toxicity management for ADCs. Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based combinations, along with emerging therapies and the latest clinical data.   Topics also include:  • Efficacy and safety of IO and IO combinations in HCC • How to select between the two 1st-line IO-based treatment options based on clinical factors • Future treatment in unresectable HCC   Clinical Takeaways • Two 1st-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape • Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies • Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen (single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up • IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary • In clinical practice, treatment choice should be individualised, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits   Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the groundbreaking INAVO120 study. Join us as we chat with Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center. We explored the study design, key findings, and the implications of this new treatment option for patients with PIK3CA mutations. Key topics discussed include: •⁠  ⁠Overview of the INAVO120 study and its significance •⁠  ⁠The unique patient population targeted in the study •⁠  ⁠Key findings, including the impressive improvement in progression-free survival (PFS) •⁠  ⁠Side effects and management strategies for patients •⁠  ⁠The importance of genetic testing in treatment decisions Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #OncologyBrothers #BreastCancer #ENAVOLacib #PIK3CA #CancerResearch #MedicalPodcast #Oncology Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rohit and Rahul Gosain are joined by Dr. Eileen O'Reilly, a leading medical oncologist and section head of hepatobiliary and pancreatic cancer at Memorial Sloan Kettering Cancer Center. Together, they delve into the complex treatment landscape of pancreatic cancer.   Episode Highlights: ⁠ ⁠The initial workup for newly diagnosed pancreatic cancer patients, including the importance of imaging and genetic testing. ⁠ ⁠Treatment paradigms for early-stage, borderline resectable, and metastatic pancreatic cancer. ⁠ ⁠The role of multi-agent chemotherapy, including modified FOLFIRINOX and gemcitabine-nab-paclitaxel. ⁠ ⁠Insights into managing patients with high bilirubin levels and the considerations for dose adjustments. ⁠ ⁠The emerging role of targeted therapies and the significance of comprehensive genetic testing in treatment decisions.   Join us as we explore the latest standards of care, the importance of a multidisciplinary approach, and the potential of new therapies in improving outcomes for patients with pancreatic cancer.   Don't forget to like, subscribe, and check out our other episodes for more insights on oncology topics, conference highlights, and recent treatment approvals!   Website: http://www.oncbrothers.com/   X/Twitter: https://twitter.com/oncbrothers   Contact us at info@oncbrothers.com

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Neil Iyengar, a medical oncologist from Memorial Sloan Kettering Cancer Center, to discuss the critical role of nutrition and exercise in cancer care and recurrence prevention. They tackle common questions from cancer survivors about lifestyle modifications that can help reduce the risk of cancer recurrence. With the current hype around various diets, the discussion delves into the evidence surrounding dietary patterns, exercise, and their impact on overall health and cancer outcomes. Key topics included: •⁠  ⁠The mixed evidence regarding diet and exercise in preventing cancer recurrence. •⁠  ⁠The limitations of BMI as a measure of health and its implications in cancer studies. •⁠  ⁠Insights from recent breast cancer trials on diet and survival rates. •⁠  ⁠The importance of social determinants of health in dietary recommendations. •⁠  ⁠Practical dietary guidelines and the significance of high-fiber, fruit-and-vegetable-rich diets. Dr. Iyengar emphasized the need for ongoing research to provide more specific dietary recommendations for different cancer types and highlights resources available for patients and healthcare providers. Join us for an informative discussion that aimed to empower cancer patients and healthcare professionals with knowledge about lifestyle interventions that can enhance quality of life and potentially improve cancer outcomes. Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers!   Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com